Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 17/20 | 0.41 |
| ▸ | F2 | P00734 | 3/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | F9 | P00740 | 2/20 | 0.38 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.38 |
| ▸ | F5 | P12259 | 1/20 | 0.38 |
| ▸ | PROC | P04070 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22729958 | 0.93 | NR2E1 (0.39) | NR2E1F10F2ABL1F9 | |
| SCHEMBL4269788 | 0.85 | NR2E1 (0.47) | NR2E1F10F2ABL1KDM4E | |
| SCHEMBL710630 | 0.78 | NR2E1 (0.54) | NR2E1F10F2KDM4EALDH1A1 | |
| SCHEMBL5395497 | 0.78 | F10 (0.43) | F10F2F9CTRB1F5 | |
| SCHEMBL6258733 | 0.76 | MAPT (0.40) | F10F2F9CTRB1F5 | |
| SCHEMBL16361760 | 0.71 | CYP3A4 (0.43) | F10ALDH1A1 | |
| SCHEMBL1028976 | 0.71 | F10 (0.45) | F10F2F9CTRB1F5 | |
| SCHEMBL8268238 | 0.70 | F10 (0.43) | F10F2KDM4EALDH1A1 | |
| SCHEMBL1098395 | 0.69 | F10 (0.40) | F10F2ABL1 | |
| SCHEMBL30950869 | 0.68 | TACR1 (0.40) | NR2E1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361232-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | TAKEDA PHARMACEUTICALS USA INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20220081440-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2022-03-17 | — | — | US | disclosed |
| EP-3747441-A1 | BICYCLIC HETEROARYL COMPOUNDS | ARIAD Pharmaceuticals, Inc. (US) | 2020-12-09 | — | — | EP | disclosed |
| US-20200231588-A1 | Bicyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. | 2020-07-23 | — | — | US | disclosed |
| US-20190031656-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2019-01-31 | — | — | US | disclosed |
| EP-3417912-A1 | BICYCLIC HETEROARYL COMPOUNDS | ARIAD Pharmaceuticals, Inc. (US) | 2018-12-26 | — | — | EP | disclosed |
| US-20170369446-A1 | MONOCYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMA INC (US) | 2017-12-28 | — | — | US | disclosed |
| US-20160368917-A1 | Bicyclic Heteroaryl Compounds | ARIAD PHARMA INC (US) | 2016-12-22 | — | — | US | disclosed |
| US-9278971-B2 | Substituted acetylenic pyrazolo[1,5-a]pyrimidines as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| EP-2024366-B1 | MONOCYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMA INC (US) | 2015-09-16 | — | — | EP | disclosed |
| US-20120135986-A1 | Bicyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-8114874-B2 | Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20090176781-A1 | Acetylenic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
| US-20090149471-A1 | Monocyclic Heterocyclic Compounds | ARIAD PHARMACEUTICALS, INC. | 2009-06-11 | — | — | US | disclosed |
| EP-2023933-A2 | ACETYLENIC HETEROARYL COMPOUNDS | ARIAD PHARMACEUTICALS, INC. (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007133560-A9 | ACETYLENIC HETEROARYL COMPOUNDS | ARIAD PHARMA INC (US) | 2008-11-13 | — | — | WO | disclosed |
| EP-1973545-A2 | BICYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMACEUTICALS, INC. (US) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007133560-A2 | ACETYLENIC HETEROARYL COMPOUNDS | ARIAD PHARMACEUTICALS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2007-08-16 | — | — | US | disclosed |
| WO-2007075869-A2 | BICYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149471-A1 | Monocyclic Heterocyclic Compounds | CYP11B2, CYP3A5, CYP1A2 | NR2E1 1868/4885F10 1139/4885F2 123/4885 |
| US-20090176781-A1 | Acetylenic Heteroaryl Compounds | NAT1, AADAC, ACACA | NR2E1 1890/4885F10 1611/4885F2 785/4885 |
| US-20220081440-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | MAP4K2, MAP3K19, MAP3K1 | NR2E1 2434/4885F10 2850/4885F2 4077/4885 |
| US-20160368917-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | NR2E1 1806/4885F10 1700/4885F2 124/4885 |
| US-20190031656-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | MAP4K2, MAP3K19, MAP3K1 | NR2E1 2434/4885F10 2850/4885F2 4077/4885 |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | CYP3A43, CYP11B2, CYP2F1 | NR2E1 1806/4885F10 1700/4885F2 124/4885 |
| US-20200231588-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | NR2E1 1806/4885F10 1700/4885F2 124/4885 |
| US-20170369446-A1 | MONOCYCLIC HETEROARYL COMPOUNDS | CYP3A43, CYP2F1, CYP11B2 | NR2E1 1748/4885F10 1796/4885F2 168/4885 |
| US-20120135986-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | NR2E1 1806/4885F10 1700/4885F2 124/4885 |
| US-20250361232-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | MAP4K2, MAP3K19, MAP3K1 | NR2E1 2434/4885F10 2850/4885F2 4077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.